LRP1 Controls Biosynthetic and Endocytic Trafficking of Neuronal Prion Protein
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Harnessing Low-Density Lipoprotein Receptor Protein 6 (LRP6) Genetic Variation and Wnt Signaling for Innovative Diagnostics in Complex Diseases
OPEN The Pharmacogenomics Journal (2018) 18, 351–358 www.nature.com/tpj REVIEW Harnessing low-density lipoprotein receptor protein 6 (LRP6) genetic variation and Wnt signaling for innovative diagnostics in complex diseases Z-M Wang1,2, J-Q Luo1,2, L-Y Xu3, H-H Zhou1,2 and W Zhang1,2 Wnt signaling regulates a broad variety of processes in both embryonic development and various diseases. Recent studies indicated that some genetic variants in Wnt signaling pathway may serve as predictors of diseases. Low-density lipoprotein receptor protein 6 (LRP6) is a Wnt co-receptor with essential functions in the Wnt/β-catenin pathway, and mutations in LRP6 gene are linked to many complex human diseases, including metabolic syndrome, cancer, Alzheimer’s disease and osteoporosis. Therefore, we focus on the role of LRP6 genetic polymorphisms and Wnt signaling in complex diseases, and the mechanisms from mouse models and cell lines. It is also highly anticipated that LRP6 variants will be applied clinically in the future. The brief review provided here could be a useful resource for future research and may contribute to a more accurate diagnosis in complex diseases. The Pharmacogenomics Journal (2018) 18, 351–358; doi:10.1038/tpj.2017.28; published online 11 July 2017 INTRODUCTION signaling pathways and expressed in various target organs.1 LDLR- The Wnt1 gene was identified in 1982. Ensuing studies in related proteins 5/6 (LRP5/6) belong to this large family and Drosophila and Xenopus unveiled a highly conserved Wnt/ function as co-receptors of the Wnt/β-catenin pathway. These β-catenin pathway, namely, canonical Wnt signaling. -
LRP1 Shedding in Human Brain: Roles of ADAM10 and ADAM17 Qiang Liu Washington University School of Medicine in St
Washington University School of Medicine Digital Commons@Becker ICTS Faculty Publications Institute of Clinical and Translational Sciences 2009 LRP1 shedding in human brain: roles of ADAM10 and ADAM17 Qiang Liu Washington University School of Medicine in St. Louis Juan Zhang Washington University School of Medicine in St. Louis Hien Tran Washington University School of Medicine in St. Louis Marcel M. Verbeek Radboud University Nijmegen Medical Centre Karina Reiss Christian-Albrecht University Kiel See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/icts_facpubs Part of the Medicine and Health Sciences Commons Recommended Citation Liu, Qiang; Zhang, Juan; Tran, Hien; Verbeek, Marcel M.; Reiss, Karina; Estus, Steven; and Bu, Guojun, "LRP1 shedding in human brain: roles of ADAM10 and ADAM17". Molecular Neurodegeneration, 17. 2009. Paper 85. https://digitalcommons.wustl.edu/icts_facpubs/85 This Article is brought to you for free and open access by the Institute of Clinical and Translational Sciences at Digital Commons@Becker. It has been accepted for inclusion in ICTS Faculty Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Qiang Liu, Juan Zhang, Hien Tran, Marcel M. Verbeek, Karina Reiss, Steven Estus, and Guojun Bu This article is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/icts_facpubs/85 Molecular Neurodegeneration BioMed Central Research article Open Access LRP1 shedding -
The LRP6 Rs2302685 Polymorphism Is Associated with Increased Risk Of
Xu et al. Lipids in Health and Disease 2014, 13:94 http://www.lipidworld.com/content/13/1/94 RESEARCH Open Access The LRP6 rs2302685 polymorphism is associated with increased risk of myocardial infarction Shun Xu1,2,3, Jie Cheng1,2,3, Yu-ning Chen1,2,3, Keshen Li4, Ze-wei Ma1,2, Jin-ming Cen5, Xinguang Liu1,2,3, Xi-li Yang5, Can Chen6 and Xing-dong Xiong1,2,3* Abstract Background: Abnormal lipids is one of the critical risk factors for myocardial infarction (MI), however the role of genetic variants in lipid metabolism-related genes on MI pathogenesis still requires further investigation. We herein genotyped three SNPs (LRP6 rs2302685, LDLRAP1 rs6687605, SOAT1 rs13306731) in lipid metabolism-related genes, aimed to shed light on the influence of these SNPs on individual susceptibility to MI. Methods: Genotyping of the three SNPs (rs2302685, rs6687605 and rs13306731) was performed in 285 MI cases and 650 control subjects using polymerase chain reaction–ligation detection reaction (PCR–LDR) method. The association of these SNPs with MI and lipid profiles was performed with SPSS software. Results: Multivariate logistic regression analysis showed that C allele (OR = 1.62, P = 0.039) and the combined CT/CC genotype (OR = 1.67, P = 0.035) of LRP6 rs2302685 were associated with increased MI risk, while the other two SNPs had no significant effect. Further stratified analysis uncovered a more evident association with MI risk among younger subjects (≤60 years old). Fascinatingly, CT/CC genotype of rs2302685 conferred increased LDL-C levels compared to TT genotype (3.0 mmol/L vs 2.72 mmol/L) in younger subjects. -
Reconfiguring Nature's Cholesterol Accepting Lipoproteins As
nanomaterials Review Reconfiguring Nature’s Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents , Skylar T. Chuang y z, Siobanth Cruz y and Vasanthy Narayanaswami * Department of Chemistry and Biochemistry, California State University, Long Beach, 1250 Bellflower Blvd, Long Beach, CA 90840, USA; [email protected] (S.T.C.); [email protected] (S.C.) * Correspondence: [email protected]; Tel.: +1-562-985-4953; Fax: +1-562-985-8557 These authors contributed equally to this work. y Current address: Department of Chemistry and Chemical Biology, Rutgers University, 123 Bevier Road, z Piscataway, NJ 08854, USA. Received: 2 March 2020; Accepted: 29 April 2020; Published: 8 May 2020 Abstract: Apolipoproteins are critical structural and functional components of lipoproteins, which are large supramolecular assemblies composed predominantly of lipids and proteins, and other biomolecules such as nucleic acids. A signature feature of apolipoproteins is the preponderance of amphipathic α-helical motifs that dictate their ability to make extensive non-covalent inter- or intra-molecular helix–helix interactions in lipid-free states or helix–lipid interactions with hydrophobic biomolecules in lipid-associated states. This review focuses on the latter ability of apolipoproteins, which has been capitalized on to reconstitute synthetic nanoscale binary/ternary lipoprotein complexes composed of apolipoproteins/peptides and lipids that mimic native high-density lipoproteins (HDLs) with the goal to transport drugs. It traces the historical development of our understanding of these nanostructures and how the cholesterol accepting property of HDL has been reconfigured to develop them as drug-loading platforms. The review provides the structural perspective of these platforms with different types of apolipoproteins and an overview of their synthesis. -
Management of Brain and Leptomeningeal Metastases from Breast Cancer
International Journal of Molecular Sciences Review Management of Brain and Leptomeningeal Metastases from Breast Cancer Alessia Pellerino 1,* , Valeria Internò 2 , Francesca Mo 1, Federica Franchino 1, Riccardo Soffietti 1 and Roberta Rudà 1,3 1 Department of Neuro-Oncology, University and City of Health and Science Hospital, 10126 Turin, Italy; [email protected] (F.M.); [email protected] (F.F.); riccardo.soffi[email protected] (R.S.); [email protected] (R.R.) 2 Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, 70121 Bari, Italy; [email protected] 3 Department of Neurology, Castelfranco Veneto and Treviso Hospital, 31100 Treviso, Italy * Correspondence: [email protected]; Tel.: +39-011-6334904 Received: 11 September 2020; Accepted: 10 November 2020; Published: 12 November 2020 Abstract: The management of breast cancer (BC) has rapidly evolved in the last 20 years. The improvement of systemic therapy allows a remarkable control of extracranial disease. However, brain (BM) and leptomeningeal metastases (LM) are frequent complications of advanced BC and represent a challenging issue for clinicians. Some prognostic scales designed for metastatic BC have been employed to select fit patients for adequate therapy and enrollment in clinical trials. Different systemic drugs, such as targeted therapies with either monoclonal antibodies or small tyrosine kinase molecules, or modified chemotherapeutic agents are under investigation. Major aims are to improve the penetration of active drugs through the blood–brain barrier (BBB) or brain–tumor barrier (BTB), and establish the best sequence and timing of radiotherapy and systemic therapy to avoid neurocognitive impairment. Moreover, pharmacologic prevention is a new concept driven by the efficacy of targeted agents on macrometastases from specific molecular subgroups. -
Endothelial LRP1 Transports Amyloid-Β1–42 Across the Blood- Brain Barrier
Endothelial LRP1 transports amyloid-β1–42 across the blood- brain barrier Steffen E. Storck, … , Thomas A. Bayer, Claus U. Pietrzik J Clin Invest. 2016;126(1):123-136. https://doi.org/10.1172/JCI81108. Research Article Neuroscience According to the neurovascular hypothesis, impairment of low-density lipoprotein receptor–related protein-1 (LRP1) in brain capillaries of the blood-brain barrier (BBB) contributes to neurotoxic amyloid-β (Aβ) brain accumulation and drives Alzheimer’s disease (AD) pathology. However, due to conflicting reports on the involvement of LRP1 in Aβ transport and the expression of LRP1 in brain endothelium, the role of LRP1 at the BBB is uncertain. As global Lrp1 deletion in mice is lethal, appropriate models to study the function of LRP1 are lacking. Moreover, the relevance of systemic Aβ clearance to AD pathology remains unclear, as no BBB-specific knockout models have been available. Here, we developed transgenic mouse strains that allow for tamoxifen-inducible deletion of Lrp1 specifically within brain endothelial cells (Slco1c1- CreERT2 Lrp1fl/fl mice) and used these mice to accurately evaluate LRP1-mediated Aβ BBB clearance in vivo. Selective 125 deletion of Lrp1 in the brain endothelium of C57BL/6 mice strongly reduced brain efflux of injected [ I] Aβ1–42. Additionally, in the 5xFAD mouse model of AD, brain endothelial–specific Lrp1 deletion reduced plasma Aβ levels and elevated soluble brain Aβ, leading to aggravated spatial learning and memory deficits, thus emphasizing the importance of systemic Aβ elimination via the BBB. Together, our results suggest that receptor-mediated Aβ BBB clearance may be a potential target for treatment and prevention of Aβ brain accumulation in AD. -
Over-Expression of Low-Density Lipoprotein Receptor-Related Protein-1 Is Associated with Poor Prognosis and Invasion in Pancreatic Ductal Adenocarcinoma
Pancreatology 19 (2019) 429e435 Contents lists available at ScienceDirect Pancreatology journal homepage: www.elsevier.com/locate/pan Over-expression of low-density lipoprotein receptor-related Protein-1 is associated with poor prognosis and invasion in pancreatic ductal adenocarcinoma Ali Gheysarzadeh a, Amir Ansari a, Mohammad Hassan Emami b, * Amirnader Emami Razavi c, Mohammad Reza Mofid a, a Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran b Gastrointestinal and Hepatobiliary Diseases Research Center, Poursina Hakim Research Institute for Health Care Development, Isfahan, Iran c Iran National Tumor Bank, Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran article info abstract Article history: Background: Low-density lipoprotein receptor-Related Protein-1 (LRP-1) has been reported to involve in Received 1 December 2018 tumor development. However, its role in pancreatic cancer has not been elucidated. The present study Received in revised form was designed to evaluate the expression of LRP-1 in Pancreatic Ductal Adenocarcinoma Cancer (PDAC) as 16 February 2019 well as its association with prognosis. Accepted 23 February 2019 Methods: Here, 478 pancreatic cancers were screened for suitable primary PDAC tumors. The samples Available online 14 March 2019 were analyzed using qRT-PCR, western blotting, and Immunohistochemistry (IHC) staining as well as LRP-1 expression in association with clinicopathological features. Keywords: PDAC Results: The relative LRP-1 mRNA expression was up-regulated in 82.3% (42/51) of the PDAC tumors and ± fi ± LRP-1 its expression (3.72 1.25) was signi cantly higher than that in pancreatic normal margins (1.0 0.23, Prognosis P < 0.05). -
Astrocytic LRP1 Mediates Brain Aßclearance and Impacts Amyloid
The Journal of Neuroscience, April 12, 2017 • 37(15):4023–4031 • 4023 Neurobiology of Disease Astrocytic LRP1 Mediates Brain A Clearance and Impacts Amyloid Deposition Chia-Chen Liu,1 Jin Hu,1,3 Na Zhao,1 XJian Wang,1 Na Wang,1,3 XJohn R. Cirrito,2 Takahisa Kanekiyo,1 David M. Holtzman,2 and Guojun Bu1,3 1Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, 2Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, and 3Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of Medicine, Xiamen University, Xiamen, Fujian, 361102 China Accumulation and deposition of amyloid- (A) in the brain represent an early and perhaps necessary step in the pathogenesis of Alzheimer’s disease (AD). A accumulation leads to the formation of A aggregates, which may directly and indirectly lead to eventual neurodegeneration. While A production is accelerated in many familial forms of early-onset AD, increasing evidence indicates that impaired clearance of A is more evident in late-onset AD. To uncover the mechanisms underlying impaired A clearance in AD, we examined the role of low-density lipoprotein receptor-related protein 1 (LRP1) in astrocytes. Although LRP1 has been shown to play critical roles in brain A metabolism in neurons and vascular mural cells, its role in astrocytes, the most abundant cell type in the brain responsible for maintaining neuronal homeostasis, remains unclear. Here, we show that astrocytic LRP1 plays a critical role in brain A clearance. LRP1 knockdown in primary astrocytes resulted in decreased cellular A uptake and degradation. -
Lrp1 Modulators
Last updated on February 14, 2021 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Lrp1 Modulators Evidence Summary Lrp1 has a variety of essential functions, mediated by a diverse array of ligands. Therapeutics will need to target specific interactions. Neuroprotective Benefit: Lrp1-mediated interactions promote Aβ clearance, Aβ generation, tau propagation, brain glucose utilization, and brain lipid homeostasis. The therapeutic effect will depend on the interaction targeted. Aging and related health concerns: Lrp1 plays mixed roles in cardiovascular diseases and cancer, dependent on context. Lrp1 is dysregulated in metabolic disease, which may contribute to insulin resistance. Safety: Broad-spectrum Lrp1 modulators are untenable therapeutics due to the high potential for extensive side effects. Therapies that target a specific Lrp1-ligand interaction are expected to have a better therapeutic profile. 1 Last updated on February 14, 2021 Availability: Research use Dose: N/A Chemical formula: N/A S16 is in clinical trials MW: N/A Half life: N/A BBB: Angiopep is a peptide that facilitates BBB penetrance by interacting with Lrp1 Clinical trials: S16, an Lrp1 Observational studies: sLrp1 levels are agonist was tested in healthy altered in Alzheimer’s disease, volunteers (n=10) in a Phase 1 cardiovascular disease, and metabolic study. -
LRP1 Influences Trafficking of N-Type Calcium Channels Via Interaction
www.nature.com/scientificreports OPEN LRP1 influences trafficking of N-type calcium channels via interaction with the auxiliary α2δ-1 Received: 17 November 2016 Accepted: 30 January 2017 subunit Published: 03 March 2017 Ivan Kadurin, Simon W. Rothwell, Beatrice Lana, Manuela Nieto-Rostro & Annette C. Dolphin 2+ Voltage-gated Ca (CaV) channels consist of a pore-forming α1 subunit, which determines the main functional and pharmacological attributes of the channel. The CaV1 and CaV2 channels are associated with auxiliary β- and α2δ-subunits. The molecular mechanisms involved in α2δ subunit trafficking, and the effect ofα 2δ subunits on trafficking calcium channel complexes remain poorly understood. Here we show that α2δ-1 is a ligand for the Low Density Lipoprotein (LDL) Receptor-related Protein-1 (LRP1), a multifunctional receptor which mediates trafficking of cargoes. This interaction with LRP1 is direct, and is modulated by the LRP chaperone, Receptor-Associated Protein (RAP). LRP1 regulates α2δ binding to gabapentin, and influences calcium channel trafficking and function. Whereas LRP1 alone reducesα 2δ-1 trafficking to the cell-surface, the LRP1/RAP combination enhances mature glycosylation, proteolytic processing and cell-surface expression of α2δ-1, and also increase plasma-membrane expression and function of CaV2.2 when co-expressed with α2δ-1. Furthermore RAP alone produced a small increase in cell-surface expression of CaV2.2, α2δ-1 and the associated calcium currents. It is likely to be interacting with an endogenous member of the LDL receptor family to have these effects. Our findings now provide a key insight and new tools to investigate the trafficking of calcium channelα 2δ subunits. -
RISK ASSESSMENT and DIAGNOSIS for EARLY ATHEROSCLEROSIS
RISK ASSESSMENT and DIAGNOSIS for 84 EARLY ATHEROSCLEROSIS/DYSLIPIDEMIAS [Genes ] AtheroGxOne™ is a genetic test to detect mutations responsible for monogenic diseases of early atherosclerosis. • Panel genes affect plasma levels of lipids (total cholesterol, LDL, HDL, triglycerides) and blood sugar. • Targeted diseases have a high impact on cardiovascular risk since they appear at an early age and indicate poor prognosis without aggressive medical intervention. • The probability of identifying the responsible mutation in patients who meet clinical criteria of familial hypercholesterolemia ranges from 60% to 80%.1,2,3 Panel Designed For Patients Who Have Or May Have: AtheroGxOneTM Gene List • Premature coronary artery disease (men < 50 years old; women < 60 years old) ABCA1 CIDEC KLF11 PDX1 • Suspected Familial Hypercholesterolemia ABCB1 COQ2 LCAT PLIN1 • Suspected Familial Hypertriglyceridemia ABCG1 CPT2 LDLR PLTP • Mixed Hyperlipidemias ABCG5 CYP2D6 LDLRAP1 PNPLA2 • Abnormally high LDL levels or low HDL ABCG8 CYP3A4 LEP PPARA • Maturity-Onset Diabetes of the Young (MODY) AGPAT2 CYP3A5 LIPA PPARG AKT2 EIF2AK3 LIPC PTF1A AMPD1 FOXP3 LMF1 PTRF ANGPTL3 GATA6 LMNA PYGM APOA1 GCK LPA RFX6 APOA5 GLIS3 LPL RYR1 APOB GPD1 LRP6 SAR1B APOC2 GPIHBP1 MEF2A SCARB1 APOC3 HNF1A MTTP SLC22A8 APOE HNF1B MYLIP SLC25A40 BLK HNF4A NEUROD1 SLC2A2 BSCL2 IER3IP1 NEUROG3 SLCO1B1 CAV1 INS NPC1L1 TBC1D4 CEL INSIG2 PAX4 TRIB1 CETP INSR PCDH15 WFS1 Atherosclerosis is defined as the buildup of plaque within arteries CH25H KCNJ11 PCSK9 ZMPSTE24 that can lead to heart attack, stroke, or even death. Approximately, 5% of cardiac arrests in individuals younger than 60 years old can be attributed to genetic mutations included in this panel; this number rises up to 20% in individuals younger than 45 years old.4,5 1. -
Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
cancers Review Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches Alessia Pellerino 1,* , Priscilla K. Brastianos 2, Roberta Rudà 1,3 and Riccardo Soffietti 1 1 Department of Neuro-Oncology, University and City of Health and Science Hospital, 10126 Turin, Italy; [email protected] (R.R.); riccardo.soffi[email protected] (R.S.) 2 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02115, USA; [email protected] 3 Department of Neurology, Castelfranco Veneto and Brain Tumor Board Treviso Hospital, 31100 Treviso, Italy * Correspondence: [email protected]; Tel.: +39-011-633-4904 Simple Summary: Leptomeningeal metastases are a devastating complication of solid tumors with poor survival, regardless of the type of treatments. The limited efficacy of targeted agents is due to the molecular divergence between leptomeningeal recurrences and primary site, as well as the presence of a heterogeneous blood-brain barrier and blood-tumor barrier that interfere with the penetration of drugs into the brain. The diagnosis of leptomeningeal metastases is achieved by neurological examination, and/or brain and spinal magnetic resonance, and/or a positive cerebrospinal fluid cytology. The presence of neoplastic cells in the cerebrospinal fluid examination is the gold-standard for the diagnosis of leptomeningeal metastases; however, novel techniques known as “liquid biopsy” aim to improve the sensitivity and specificity in detecting circulating neoplastic cells or DNA in the cerebrospinal fluid. Targeted therapies and immunotherapies have changed the natural history Citation: Pellerino, A.; Brastianos, of metastatic solid tumors, including lung, breast cancer, and melanoma. Targeting actionable P.K.; Rudà, R.; Soffietti, R.